Novo Nordisk A/S (LON:0TDD)

Market Cap	156.41B -46.7%
Revenue (ttm)	36.10B +6.4%
Net Income	11.97B +1.4%
EPS	2.69 +1.8%
Shares Out	n/a
PE Ratio	13.07
Forward PE	14.39
Dividend	0.94 (1.97%)
Ex-Dividend Date	Aug 18, 2025

Volume	134,168
Average Volume	482,074
Open	48.39
Previous Close	48.61
Day's Range	47.04 - 48.89
52-Week Range	41.45 - 93.80
Beta	0.36
RSI	38.47
Earnings Date	Feb 4, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 69,150
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0TDD

Financial Performance

In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.

Financial numbers in DKK